Illumina reported strong third-quarter results, exceeding revenue and EPS guidance, driven by robust performance across its clinical business and successful transition to the NovaSeq X platform.

• Total revenue reached $1.08 billion, with 2% year-over-year growth excluding China, highlighting a recovery in demand.
• Non-GAAP operating margin improved to 24.5%, and diluted EPS increased to $1.34, reflecting strong operational efficiencies.
• Clinical sequencing consumables grew at a high single-digit rate, supported by the NovaSeq X's higher throughput capabilities.
• Initiatives in multiomics, including the launch of the Illumina Protein Prep and BioInsight, are expected to drive future growth and innovation.
• Revenue from China exceeded expectations despite export restrictions, with localized manufacturing partnerships on the horizon.